Explore the vast range of titles available.

Large panels of comprehensively characterized human cancer models, including the Cancer Cell Line Encyclopedia (CCLE), have provided a rigorous framework with which to study genetic variants, candidate targets, and small-molecule and biological therapeutics and to identify new marker-driven cancer dependencies. To improve our understanding of the molecular features that contribute to cancer phenotypes, including drug responses, here we have expanded the characterizations of cancer cell lines to include genetic, RNA splicing, DNA methylation, histone H3 modification, microRNA expression and reverse-phase protein array data for 1,072 cell lines from individuals of various lineages and ethnicities. Integration of these data with functional characterizations such as drug-sensitivity, short hairpin RNA knockdown and CRISPR–Cas9 knockout data reveals potential targets for cancer drugs and associated biomarkers. Together, this dataset and an accompanying public data portal provide a resource for the acceleration of cancer research using model cancer cell lines. The original Cancer Cell Line Encyclopedia (CCLE) is expanded with deeper characterization of over 1,000 cell lines, including genomic, transcriptomic, and proteomic data, and integration with drug-sensitivity and gene-dependency data.

Retrospective studies provide conflicting interpretations of the effect of inherited genetic factors on the prognosis of patients with breast cancer. The primary aim of this study was to determine the effect of a germline BRCA1 or BRCA2 mutation on breast cancer outcomes in patients with young-onset breast cancer. We did a prospective cohort study of female patients recruited from 127 hospitals in the UK aged 40 years or younger at first diagnosis (by histological confirmation) of invasive breast cancer. Patients with a previous invasive malignancy (except non-melanomatous skin cancer) were excluded. Patients were identified within 12 months of initial diagnosis. BRCA1 and BRCA2 mutations were identified using blood DNA collected at recruitment. Clinicopathological data, and data regarding treatment and long-term outcomes, including date and site of disease recurrence, were collected from routine medical records at 6 months, 12 months, and then annually until death or loss to follow-up. The primary outcome was overall survival for all BRCA1 or BRCA2 mutation carriers (BRCA-positive) versus all non-carriers (BRCA-negative) at 2 years, 5 years, and 10 years after diagnosis. A prespecified subgroup analysis of overall survival was done in patients with triple-negative breast cancer. Recruitment was completed in 2008, and long-term follow-up is continuing. Between Jan 24, 2000, and Jan 24, 2008, we recruited 2733 women. Genotyping detected a pathogenic BRCA mutation in 338 (12%) patients (201 with BRCA1, 137 with BRCA2). After a median follow-up of 8·2 years (IQR 6·0–9·9), 651 (96%) of 678 deaths were due to breast cancer. There was no significant difference in overall survival between BRCA-positive and BRCA-negative patients in multivariable analyses at any timepoint (at 2 years: 97·0% [95% CI 94·5–98·4] vs 96·6% [95·8–97·3]; at 5 years: 83·8% [79·3–87·5] vs 85·0% [83·5–86·4]; at 10 years: 73·4% [67·4–78·5] vs 70·1% [67·7–72·3]; hazard ratio [HR] 0·96 [95% CI 0·76–1·22]; p=0·76). Of 558 patients with triple-negative breast cancer, BRCA mutation carriers had better overall survival than non-carriers at 2 years (95% [95% CI 89–97] vs 91% [88–94]; HR 0·59 [95% CI 0·35–0·99]; p=0·047) but not 5 years (81% [73–87] vs 74% [70–78]; HR 1·13 [0·70–1·84]; p=0·62) or 10 years (72% [62–80] vs 69% [63–74]; HR 2·12 [0·82–5·49]; p= 0·12). Patients with young-onset breast cancer who carry a BRCA mutation have similar survival as non-carriers. However, BRCA mutation carriers with triple-negative breast cancer might have a survival advantage during the first few years after diagnosis compared with non-carriers. Decisions about timing of additional surgery aimed at reducing future second primary-cancer risks should take into account patient prognosis associated with the first malignancy and patient preferences. Cancer Research UK, the UK National Cancer Research Network, the Wessex Cancer Trust, Breast Cancer Now, and the PPP Healthcare Medical Trust Grant.

Telomeres play a key role in the maintenance of chromosome integrity and stability, and telomere shortening is involved in initiation and progression of malignancies. A series of epidemiological studies have examined the association between shortened telomeres and risk of cancers, but the findings remain conflicting. A dataset composed of 11,255 cases and 13,101 controls from 21 publications was included in a meta-analysis to evaluate the association between overall cancer risk or cancer-specific risk and the relative telomere length. Heterogeneity among studies and their publication bias were further assessed by the χ(2)-based Q statistic test and Egger's test, respectively. The results showed that shorter telomeres were significantly associated with cancer risk (OR = 1.35, 95% CI = 1.14-1.60), compared with longer telomeres. In the stratified analysis by tumor type, the association remained significant in subgroups of bladder cancer (OR = 1.84, 95% CI = 1.38-2.44), lung cancer (OR = 2.39, 95% CI = 1.18-4.88), smoking-related cancers (OR = 2.25, 95% CI = 1.83-2.78), cancers in the digestive system (OR = 1.69, 95% CI = 1.53-1.87) and the urogenital system (OR = 1.73, 95% CI = 1.12-2.67). Furthermore, the results also indicated that the association between the relative telomere length and overall cancer risk was statistically significant in studies of Caucasian subjects, Asian subjects, retrospective designs, hospital-based controls and smaller sample sizes. Funnel plot and Egger's test suggested that there was no publication bias in the current meta-analysis (P = 0.532). The results of this meta-analysis suggest that the presence of shortened telomeres may be a marker for susceptibility to human cancer, but single larger, well-design prospective studies are warranted to confirm these findings.

Variation in sensitivity to radiation is an inherited genetic trait. This Perspective explores the possibility of genome-wide association studies to characterize genetic profiles that predict patient response to radiotherapy. A key challenge in radiotherapy is to maximize radiation doses to cancer cells while minimizing damage to surrounding healthy tissue. As severe toxicity in a minority of patients limits the doses that can be safely given to the majority, there is interest in developing a test to measure an individual's radiosensitivity before treatment. Variation in sensitivity to radiation is an inherited genetic trait and recent progress in genotyping raises the possibility of genome-wide studies to characterize genetic profiles that predict patient response to radiotherapy.

Echo-enabled harmonic generation has been used to seed a free-electron laser and has been demonstrated up to the 75th harmonic, producing 32 nm light from a 2,400 nm laser. The production of coherent radiation at ever shorter wavelengths has been a long-standing challenge since the invention of lasers 1 , 2 and the subsequent demonstration of frequency doubling 3 . Modern X-ray free-electron lasers (FELs) use relativistic electrons to produce intense X-ray pulses on few-femtosecond timescales 4 , 5 , 6 . However, the shot noise that seeds the amplification produces pulses with a noisy spectrum and limited temporal coherence. To produce stable transform-limited pulses, a seeding scheme called echo-enabled harmonic generation (EEHG) has been proposed 7 , 8 , which harnesses the highly nonlinear phase mixing of the celebrated echo phenomenon 9 to generate coherent harmonic density modulations in the electron beam with conventional lasers. Here, we report on a demonstration of EEHG up to the 75th harmonic, where 32 nm light is produced from a 2,400 nm laser. We also demonstrate that individual harmonic amplitudes are controlled by simple adjustment of the phase mixing. Results show the potential of laser-based manipulations to achieve precise control over the coherent spectrum in future X-ray FELs for new science 10 , 11 .

Understanding fast melting of metals is important for applications such as welding and micromachining. However, fast melting leaves simulation as the only option for probing the process. Mo et al. performed ultrafast electron diffraction experiments on laser-pulsed gold films. This allowed detailed mapping of the melting process, which proceeds through two distinct regimes while the bonding behavior changes in unexpected ways. The results require adding new physical processes to high-energy melting models. Science , this issue p. 1451 The details of how gold melts are captured with ultrafast electron diffraction experiments. The ultrafast laser excitation of matters leads to nonequilibrium states with complex solid-liquid phase-transition dynamics. We used electron diffraction at mega–electron volt energies to visualize the ultrafast melting of gold on the atomic scale length. For energy densities approaching the irreversible melting regime, we first observed heterogeneous melting on time scales of 100 to 1000 picoseconds, transitioning to homogeneous melting that occurs catastrophically within 10 to 20 picoseconds at higher energy densities. We showed evidence for the heterogeneous coexistence of solid and liquid. We determined the ion and electron temperature evolution and found superheated conditions. Our results constrain the electron-ion coupling rate, determine the Debye temperature, and reveal the melting sensitivity to nucleation seeds.

Clare Turnbull and colleagues report discovery of 19 new susceptibility loci for testicular germ cell tumor (TGCT) and provide evidence for a network of physical interactions between TGCT risk variants and candidate causal genes. Their findings implicate widespread disruption of developmental transcriptional regulators in TGCT susceptibility, consistent with failed primordial germ cell differentiation as an initiating step in oncogenesis. Genome-wide association studies (GWAS) have transformed understanding of susceptibility to testicular germ cell tumors (TGCTs), but much of the heritability remains unexplained. Here we report a new GWAS, a meta-analysis with previous GWAS and a replication series, totaling 7,319 TGCT cases and 23,082 controls. We identify 19 new TGCT risk loci, roughly doubling the number of known TGCT risk loci to 44. By performing in situ Hi-C in TGCT cells, we provide evidence for a network of physical interactions among all 44 TGCT risk SNPs and candidate causal genes. Our findings implicate widespread disruption of developmental transcriptional regulators as a basis of TGCT susceptibility, consistent with failed primordial germ cell differentiation as an initiating step in oncogenesis 1 . Defective microtubule assembly and dysregulation of KIT–MAPK signaling also feature as recurrently disrupted pathways. Our findings support a polygenic model of risk and provide insight into the biological basis of TGCT.

Changes in the seasonality of precipitation over Africa have high potential for detrimental socioeconomic impacts due to high societal dependence upon seasonal rainfall. Here, for the first time we conduct a continental-scale analysis of changes in wet season characteristics under the RCP4.5 and RCP8.5 climate projection scenarios across an ensemble of CMIP5 models using an objective methodology to determine the onset and cessation of the wet season. A delay in the wet season over West Africa and the Sahel of over 5–10 days on average, and later onset of the wet season over southern Africa, is identified and associated with increasing strength of the Saharan heat low in late boreal summer and a northward shift in the position of the tropical rain belt over August–December. Over the Horn of Africa rainfall during the “short rains” season is projected to increase by over 100 mm on average by the end of the twenty-first century under the RCP8.5 scenario. Average rainfall per rainy day is projected to increase, while the number of rainy days in the wet season declines in regions of stable or declining rainfall (western and southern Africa) and remains constant in central Africa, where rainfall is projected to increase. Adaptation strategies should account for shorter wet seasons, increasing rainfall intensity, and decreasing rainfall frequency, which will have implications for crop yields and surface water supplies.

An objective technique for analysing seasonality, in terms of regime, progression and timing of the wet seasons, is applied in the evaluation of CMIP5 simulations across continental Africa. Atmosphere-only and coupled integrations capture the gross observed patterns of seasonal progression and give mean onset/cessation dates within 18 days of the observational dates for 11 of the 13 regions considered. Accurate representation of seasonality over central-southern Africa and West Africa (excluding the southern coastline) adds credence for future projected changes in seasonality here. However, coupled simulations exhibit timing biases over the Horn of Africa, with the long rains 20 days late on average. Although both sets of simulations detect biannual rainfall seasonal cycles for East and Central Africa, coupled simulations fail to capture the biannual regime over the southern West African coastline. This is linked with errors in the Gulf of Guinea sea surface temperature (SST) and deficient representation of the SST/rainfall relationship.

Ana Vega and colleagues report the results of a three-stage genome-wide association study of radiotherapy toxicity following treatment for prostate cancer. They find that susceptibility to late radiation-induced toxicity is associated with variants in the TANC1 gene at 2q24.1. There is increasing evidence supporting the role of genetic variants in the development of radiation-induced toxicity 1 . However, previous candidate gene association studies failed to elucidate the common genetic variation underlying this phenotype 2 , which could emerge years after the completion of treatment 3 . We performed a genome-wide association study on a Spanish cohort of 741 individuals with prostate cancer treated with external beam radiotherapy (EBRT). The replication cohorts consisted of 633 cases from the UK 4 and 368 cases from North America 5 . One locus comprising TANC1 (lowest unadjusted P value for overall late toxicity = 6.85 × 10 −9 , odds ratio (OR) = 6.61, 95% confidence interval (CI) = 2.23–19.63) was replicated in the second stage (lowest unadjusted P value for overall late toxicity = 2.08 × 10 −4 , OR = 6.17, 95% CI = 2.25–16.95; P combined = 4.16 × 10 −10 ). The inclusion of the third cohort gave unadjusted P combined = 4.64 × 10 −11 . These results, together with the role of TANC1 in regenerating damaged muscle, suggest that the TANC1 locus influences the development of late radiation-induced damage.